StockNews.AI
SGMT
StockNews.AI
5 hrs

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

1. Sagimet will present at the MASH Drug Development Summit. 2. Focus on denifanstat's efficacy as an FASN inhibitor. 3. AI techniques to evaluate denifanstat's anti-fibrotic effects. 4. Breakthrough Therapy designation for denifanstat validated by FDA. 5. Phase 2b results indicate promising progress in MASH treatment.

10m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentations and FDA validation of denifanstat could enhance investor confidence, similar to other successful drug presentations leading to price surges in peers like NASH biopharma stocks.

How important is it?

The article highlights crucial advancements in drug development and presents key data on denifanstat, amplifying market interest and potential impact on stock price.

Why Short Term?

Anticipation of upcoming event presentations typically has immediate effects on stock prices, as seen historically with other biopharmaceutical announcements.

Related Companies

NASHMGTXCTIC
September 10, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will give two oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit taking place September 29-October 1, 2025 in Boston, MA. The two presentations will cover combination treatment with a FASN inhibitor, and AI-based digital pathology to evaluate denifanstat anti-fibrotic effect in MASH patients respectively. Presentation Title:Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASHPresenter: Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet BiosciencesSession:Revolutionizing MASH Therapy Development by Harnessing Biomarkers & Innovative Trial Designs to Accelerate Progress Towards Effective Combination & Sequential TherapiesDate and time: Monday, September 29, 2025, 2.45pm ETKey Highlights:This presentation will focus on reviewing the preclinical activity of a FASN inhibitor combined with semaglutide or resmetirom and will highlight the efficacy of denifanstat when added to background GLP1 treatment in the Phase 2b FASCINATE-2 study. Dr. O’Farrell will also cover the planned Phase 1 PK study of denifanstat and resmetirom.   Panel Discussion:Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient OutcomesPresenter: Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet BiosciencesSession:Revolutionizing MASH Therapy Development by Harnessing Biomarkers & Innovative Trial Designs to Accelerate Progress Towards Effective Combination & Sequential TherapiesDate and time: Monday, September 29, 2025, 3.15pm ET   Presentation Title:Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced FibrosisPresenter: Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, Sagimet BiosciencesSession:Revolutionizing MASH Diagnosis Using Non-Invasive Biomarkers to Enhance Precision for Earlier Detection to Improve Patient OutcomesDate and time: Tuesday, September 30, 2025, 12.45pm ETKey Highlights:This presentation will discuss the mechanism of action for denifanstat and its robust anti-fibrotic effect in MASH patients with F3 fibrosis as well as the application of digital pathology techniques to assess this anti-fibrotic effect. Dr. Tsai will also discuss the use of zonal analysis to explore denifanstat’s potential to offer long-term clinical benefit.   About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit www.sagimet.com. About MASH Metabolic-dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there are few approved treatments. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis. Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact:Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com

Related News